CORE A: Given the size, complexity, duration, and scope involved. Core A will be fundamental in enabling the successful establishment and operation of the entire program. All costs for administrative support for the Cores and Projects are included here. Dr. James Loyd will assume ultimate administrative responsibility for the management of this Core. Administrative and clerical support for the entire program will be shared by all Project Leaders, Core Leaders and Co-Investigators. This Core will provide and maintain all of the administrative space and functions for the entire program, including but not limited to, offices for all investigators, an administrative area with secretarial and administrative support, a copy/work room, and a conference room with up to date audiovisual amenities. Administrative functions will include ordering of supplies and equipment, maintenance of all records, keeping and monitoring of budgets, maintenance of the personnel database for grant effort, interactions with University administrative offices and the NIH regarding budgetary and other administrative matters, and scheduling and organizing meetings and presentations. This Core will support all of the computer hardware and software resources for the administrative and clerical functions of the program. This Core will coordinate and support the activities of the Internal Advisory Committee and the External Scientific Advisory Board. The basic functions and objectives of the Core include: quality management of program resources, integration of the program, oversight of deliverables within the time frame, assistance with data management, and leading the vision. To achieve these objectives, detailed plans are presented for administrative structure and leadership, project management, external Scientific Advisory Board, and communication/meetings.
Pulmonary arterial hypertension (PAH) is elevated blood pressure in the lungs, which leads to right heart failure and death. No existing treatments are very effective. This Program Project Grant aims to develop new, more effective treatments based on interventions against the hormonal, metabolic, and signaling defects recently shown to form the molecular basis for disease.
|Best, D Hunter; Sumner, Kelli L; Austin, Eric D et al. (2014) EIF2AK4 mutations in pulmonary capillary hemangiomatosis. Chest 145:231-6|
|Robbins, Ivan M; Hemnes, Anna R; Pugh, Meredith E et al. (2014) High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in pulmonary hypertension. Circ Heart Fail 7:116-22|
|Brittain, Evan L; Hemnes, Anna R (2014) One generation's "junk" is another's treasure: the emerging role of microRNAs as therapeutic targets. J Heart Lung Transplant 33:233-4|
|Stearman, Robert S; Cornelius, Amber R; Lu, Xiao et al. (2014) Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension. Am J Respir Crit Care Med 189:1110-20|
|Hemnes, Anna R; Brittain, Evan L; Trammell, Aaron W et al. (2014) Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am J Respir Crit Care Med 189:325-34|
|Zhao, Min; Austin, Eric D; Hemnes, Anna R et al. (2014) An evidence-based knowledgebase of pulmonary arterial hypertension to identify genes and pathways relevant to pathogenesis. Mol Biosyst 10:732-40|
|Austin, Eric D; Loyd, James E (2014) The genetics of pulmonary arterial hypertension. Circ Res 115:189-202|
|Brittain, Evan L; Pugh, Meredith E; Wheeler, Lisa A et al. (2013) Prostanoids but not oral therapies improve right ventricular function in pulmonary arterial hypertension. JACC Heart Fail 1:300-7|
|Brittain, Evan L; Pugh, Meredith E; Wang, Li et al. (2013) Predictors of diastolic-to-wedge gradient in patients evaluated for pulmonary hypertension. PLoS One 8:e76461|
|Austin, Eric D; Loyd, James E (2013) Heritable forms of pulmonary arterial hypertension. Semin Respir Crit Care Med 34:568-80|